Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,085,243 papers from all fields of science
Search
Sign In
Create Free Account
Anti-EGFR Monoclonal Antibody Mixture Sym004
Known as:
Futuximab/Zatuximab
, Sym004
A mixture of two recombinant IgG1 antibodies directed against different epitopes in the epidermal growth factor receptor (EGFR) extracellular domain…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized…
C. Montagut
,
G. Argilés
,
+29 authors
J. Tabernero
JAMA Oncology
2018
Corpus ID: 5009743
Importance Acquired resistance to anti-EGFR therapy (epidermal growth factor receptor) is frequently due to RAS and EGFR…
Expand
Review
2017
Review
2017
EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise
M. Westphal
,
C. Maire
,
K. Lamszus
CNS Drugs
2017
Corpus ID: 11657591
The receptor for epidermal growth factor (EGFR) is a prime target for cancer therapy across a broad variety of tumor types. As it…
Expand
Review
2017
Review
2017
Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery
A. Dokala
,
S. Thakur
Oncogene
2017
Corpus ID: 27961580
The epidermal growth factor receptor (EGFR) is a transmembrane receptor with tyrosine kinase activity involved in regulation of…
Expand
Highly Cited
2016
Highly Cited
2016
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
F. J. Sánchez-Martín
,
B. Bellosillo
,
+19 authors
C. Montagut
Clinical Cancer Research
2016
Corpus ID: 32870915
Purpose: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic…
Expand
Highly Cited
2015
Highly Cited
2015
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.
R. Dienstmann
,
A. Patnaik
,
+16 authors
J. Tabernero
Cancer Discovery
2015
Corpus ID: 8308482
UNLABELLED Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms…
Expand
2015
2015
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck
J. Machiels
,
P. Specenier
,
+11 authors
T. Gauler
Cancer Chemotherapy and Pharmacology
2015
Corpus ID: 22247237
AbstractPurposeThe purpose of the trial was to assess the efficacy and tolerability of Sym004, a novel 1:1 mixture of two…
Expand
Highly Cited
2013
Highly Cited
2013
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
M. Iida
,
T. Brand
,
+7 authors
D. Wheeler
Neoplasia
2013
Corpus ID: 30833543
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab…
Expand
Highly Cited
2011
Highly Cited
2011
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor
K. Koefoed
,
L. Steinaa
,
+8 authors
M. W. Pedersen
mAbs
2011
Corpus ID: 19580568
The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer…
Expand
2011
2011
Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor
N. Skartved
,
H. Jacobsen
,
+5 authors
M. Kragh
Clinical Cancer Research
2011
Corpus ID: 17046621
Purpose: Sym004 is a novel therapeutic antibody mixture product comprising two unmarketed monoclonal antibodies (mAb) targeting…
Expand
Highly Cited
2010
Highly Cited
2010
Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
M. W. Pedersen
,
H. Jacobsen
,
+4 authors
M. Kragh
Cancer Research
2010
Corpus ID: 5405260
Epidermal growth factor receptor (EGFR) is a validated therapeutic target in cancer and EGFR antagonists with greater…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE